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replication rate for multi-tissue outliers was much higher and increased with the number of tissues used for discovery ( Fig. 1c) .
We investigated the influence of rare genetic variation on extreme expression levels, focusing on the individuals of European ancestry with whole-genome sequencing data (1,144 multi-tissue outliers). Multitissue outliers were strongly enriched for nearby rare variants. The enrichment was most pronounced for structural variants, as previously described 14 , and greater for short insertions and deletions (indels) than for single-nucleotide variants (SNVs) ( Fig. 2a and Extended Data Fig. 4 ). Because most rare variants occur as heterozygotes, expression outliers driven by rare variants in cis should exhibit allele-specific expression (ASE). Both single-tissue and multi-tissue outliers were significantly enriched for ASE compared to non-outliers (see Methods; two-sided Wilcoxon rank-sum tests, each nominal P < 2.2 × 10 −16 ; Fig. 2c ). For underexpression outliers with exonic rare variants, the rare allele was generally underexpressed with respect to the common allele and conversely so for overexpression outliers, consistent with the rare variant causing the effect (two-sided Wilcoxon rank-sum tests, each nominal P < 4.0 × 10 −8 ; Extended Data Fig. 5a ). The enrichment for rare variants and ASE was stronger for multi-tissue outliers than for single-tissue outliers (Fig. 2b, c and Extended Data Fig. 6a ), especially at higher Z-score thresholds.
To characterize the properties of rare variants that correlated with large changes in gene expression, we assessed the enrichment of different classes of variants in outliers compared to non-outliers ( Supplementary  Table 3a ). Outliers were enriched, in order of signifi cance, for structural variants, variants near splice sites, introducing frameshifts, at start or stop codons, near the transcription start site and in conserved regions ( Fig. 3a) . Variants in coding regions contributed disproportionately to outlier expression; enrichments weakened for all variants types (SNVs, indels and structural variants) when excluding exonic regions (Extended Data Fig. 6b ). Additionally, 90% of stop-gain and frameshift variants were predicted to trigger nonsense-mediated decay in outliers (see Methods), suggesting a biological mechanism for these cases.
We also tested the relationship between outlier gene expression and functional annotations. Multi-tissue outliers were strongly enriched for variants in promoter or CpG-rich regions and had variants with higher conservation [15] [16] [17] [18] and CADD (combined annotation-dependent depletion) 19 scores than non-outliers. We observed weaker enrichment in enhancers and transcriptionfactor-binding sites ( Fig. 3b and Extended Data Fig. 7 ). Combining all classes of variation, other than non-conserved, non-coding, rare variants (excluded as less likely candidates for causal effects), . Lines indicate 95% Wald confidence intervals of the relative risk estimates. b, Rare SNV enrichments at increasing Z-score thresholds. Text labels indicate the number of outliers at each threshold. c, ASE at increasing Z-score thresholds. ASE is measured as the magnitude of the difference between the reference-allele ratio and the null expectation of 0.5. The non-outlier category is defined in the Methods.
Letter reSeArCH for functionally annotated rare variants (Extended Data Fig. 5c ). Some variant classes had strong directionality concordant with their expected impact: duplications caused overexpression, whereas deletions, start-and stop-codon variants and frameshifts coincided with underexpression ( Fig. 3d ). We also observed strong ASE for outliers carrying all classes of variants, except non-conserved variants ( Fig. 3e ). We hypothesized that functional, large-effect rare variants have been under recent selective pressure. As expected, we found that rare promoter variants of outliers were significantly less frequent in the UK10K cohort of 3,781 individuals 3 than rare promoter variants of non-outliers for the same genes (two-sided Wilcoxon rank-sum test, P = 0.0060; Fig. 4a ). Additionally, genes intolerant to loss-of-function and missense mutations were depleted of both multi-tissue outliers and multi-tissue expression quantitative trait loci (eQTLs; Fisher's exact test, all P < 2 × 10 −15 ; Fig. 4b and Extended Data Fig. 8a ). We observed a similar depletion in two curated disease gene lists-genes involved in heritable cardiovascular disease and genes in the guidelines of the American College of Medical Genetics and Genomics for incidental findings 20 -but not in broader gene lists ( Fig. 4c and Extended Data Fig. 8b, c) . Genes with a multi-tissue outlier were more likely to have a 
Figure 4
| Evolutionary constraint of genes with multi-tissue outliers. a, Distributions of UK10K minor allele frequencies for promoter SNVs in outlier and non-outlier individuals at genes with multi-tissue outliers. b, Odds ratio of being intolerant to loss-of-function variants for genes with multi-tissue outliers, genes with shared eQTLs (eGenes), genes reported in the genome-wide association study (GWAS) catalogue and Online Mendelian Inheritance in Man (OMIM) genes. c, Odds ratio of a gene having a multi-tissue outlier for each of eight sets of genes involved in complex traits or diseases (gene lists are described in the Methods; DDG2P: Developmental Disorders Genotype-to-Phenotype). In b and c, lines represent 95% confidence intervals (Fisher's exact test).
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multi-tissue eQTL (two-sided Wilcoxon rank-sum test, P < 2.2 × 10 −16 ; Extended Data Fig. 8d, e ), suggesting that rare and common regulatory variation influence similar genes. However, we found evidence that genes with outliers were more constrained than genes with multi-tissue eQTLs, because genes with outliers had less missense and loss-offunction variation (Tukey's range test, missense Z-score P = 0.0070, probability of loss-of-function intolerance score P = 0.032; Fig. 4b and Extended Data Fig. 8a ). This suggests that outlier expression analysis can yield unique insights into constraints on gene regulation.
Next, we sought to prioritize rare variants in each individual genome by their predicted impact on gene expression. We developed RIVER (RNA-informed variant effect on regulation), a Bayesian statistical model that jointly analyses genome and transcriptome data from the same individual to estimate the probability that a variant has regulatory impact (https://bioconductor.org/packages/release/bioc/html/RIVER. html, see Methods). RIVER uses a generative model that assumes that genomic annotations ( Supplementary Table 3b ) determine the prior probability that a variant is a functional regulatory variant, in terms of influence on gene expression, which in turn affects whether nearby genes are likely to display outlier levels of expression ( Fig. 5a ). RIVER does not require a labelled set of functional/non-functional variants; rather it derives its power from identifying expression patterns that coincide with predictive genomic annotations.
We trained RIVER on the GTEx v6p cohort, and evaluated the model on held-out pairs of individuals who shared the same rare variants. We then computed the RIVER score (the posterior probability of having a functional regulatory variant) for one individual, using both expression and genomic data, and assessed the accuracy with respect to the expression levels of the second individual that had been held out (see Methods). Incorporating expression data significantly improved prediction compared with a model that uses genomic annotations alone (area under the curve (AUC) of 0.64 and 0.54, respectively, P = 3.5 × 10 −4 ; Fig. 5b and Extended Data Fig. 9a, b) , and RIVER learned, unsupervised, to prioritize variants supported by both genomic annotations and extreme expression levels across tissues ( Fig. 5c and Extended Data Fig. 9c ). ASE was also enriched among the top RIVER hits compared with the genomic annotation model (Extended Data Fig. 9d ). Finally, even after accounting for the most informative genomic annotations or summary scores, personal expression data were highly informative of rare variant effects (average log odds ratio, 2.76; Extended Data Fig. 9e , f).
RIVER can be used to predict regulatory effects on gene expression of disease-associated variants and aid in prioritization of rare variants in disease studies. To investigate this potential, we evaluated 27 pathogenic variants from ClinVar 21 present in 21 GTEx donors ( Fig. 5c and Extended Data Fig. 10a ). Overall, pathogenic variants had RIVER scores that were higher than background variants (two-sided Wilcoxon rank-sum test, P = 3.3 × 10 −9 ; Extended Data Fig. 10b-d) , and the six that were probably regulatory variants (those not annotated as missense or as an indel within a coding region) scored in the 99.9th percentile. Several cases, which we evaluated in detail, illustrated that rare disease-causing variants can have a regulatory impact evident from RNA-sequencing data, even from healthy individuals that have those variants (in whom the variants are often heterozygous; Extended Data Fig. 10e , f). Note that RIVER trained on healthy cohorts, such as GTEx, can then be directly applied to new cohorts that include disease samples.
To experimentally validate a subset of the variants that were identified through outlier analysis, we used CRISPR-Cas9-mediated genome editing 22, 23 . In K562 cells, we tested six SNVs and matched controls in transcribed regions of genes with an outlier (see Methods and Extended Data Fig. 11a, b) , and compared the allelic ratios between mRNA and genomic DNA (gDNA), which was used as an internal control. All variants that were tested were SNVs in underexpression outliers and were therefore expected to decrease expression. Two variants were excluded owing to low cDNA and gDNA total reads counts. The four remaining SNVs in outliers all showed lower proportions of the alternate (installed) allele in the cDNA compared to the gDNA, confirming that these variants decreased expression (Extended Data Fig. 11c ).
In summary, by combining data across multiple tissues, we curated a set of gene expression outliers that replicated at higher rates and showed stronger enrichment of rare variants than those from any single tissue. We found that rare structural variants, frameshift indels, coding variants and variants near the transcription start site were most likely to have large effects on expression. However, our ability to characterize the genetic basis of multi-tissue outliers remains incomplete. Outliers without an underlying rare variant in our analysis may be due to variants in more distal regions or in annotations we did not consider, or may be attributable to residual technical or environmental effects.
Although variant interpretation remains challenging, RIVER demonstrates the value of incorporating personal gene expression data to examine the consequences of rare variants that may be uncertain based on the sequence alone. Our results suggest that a general approach can be applied to studies that supplement genome sequencing with other molecular phenotypes, such as methylation [24] [25] [26] and histone modification 27,28 . We anticipate that such integrative approaches will be Letter reSeArCH METHODS Study population. All human subjects were deceased donors. Informed consent was obtained for all donors via next-of-kin consent to permit the collection and banking of de-identified tissue samples for scientific research. The research protocol was reviewed by Chesapeake Research Review Inc., Roswell Park Cancer Institute's Office of Research Subject Protection, and the institutional review board of the University of Pennsylvania. We used the RNA-seq, allele-specific expression, and whole-genome sequencing (WGS) data from the v6p release of the GTEx project. The generation of these data are described in the supplementary information of ref. 12 . Correction for technical confounders. We restricted our expression analyses to the 449 individuals and 44 tissues for which sex and the top three genotype principal components, which capture major population stratification, were available. For each tissue, we log 2 -transformed all expression values (log 2 (RPKM + 2)), where RPKM is the number of reads per kilobase of transcript per million mapped reads. We then standardized the expression of each gene to prevent shrinkage of outlier expression values caused by quantile normalization. To remove unmeasured batch effects and other confounders, for each tissue separately, we estimated hidden factors using PEER 13 on the transformed expression values. In each tissue, we defined expressed genes and corrected for the same number of PEER factors as in the GTEx eQTL analyses (see supplementary information of ref. 12 ). We regressed out the PEER factors, the top three genotype principal components and sex (where appropriate) from the transformed expression data for each tissue using the following linear model:
where Y g is the transformed expression of a given gene g, μ g is the mean expression level for the gene, P n is the nth PEER factor, G 1 , G 2 , G 3 are the top three genotype principal components, and S is the sex covariate. We assumed the residual vector ε g follows the multivariate normal distribution ε g ~ N(0, σ 2 I). Finally, we standardized the expression residuals ε g for each gene, which yielded Z-scores.
To better understand the effect of PEER correction on the removal of technical and biological confounders, we compared the PEER factors in each tissue separately to pre-collected sample and subject covariates. We considered the subset of covariates with > 50 observations in at least 31 tissues, where we first selected covariates with more than one unique entry in each tissue. For categorical covariates, we only considered categories with more than 20 observations. For each PEER factor and each covariate, we fit a linear model with the PEER factor as the response and the covariate as the predictor. From this model, we computed the proportion of that PEER factor's variance explained by the covariate as the adjusted R 2 :
where p and n are the number of parameters and samples, respectively, and
SS T and SS R refer to the total and residual sums of squares, respectively. To quantify the degree to which each covariate was captured by the combination of all PEER factors, genotype principal components and sex (where appropriate) for each tissue, we considered the expression component regressed out from the uncorrected data:
For each covariate, we then fit a linear model with W g as the response and the covariate as the predictor. We assessed the proportion of the variance of W g explained by each covariate by computing the adjusted R 2 for the covariate across all genes. We used the formula above, but summed across all genes to compute SS T and SS R .
To assess the impact of PEER correction on rare variant enrichment, we also tried removing either the top five PEER factors for each tissue or no PEER factors. We then performed multi-tissue outlier calling and tested the enrichment of rare and common variants in the two partially corrected datasets (see 'Enrichment of rare and common variants near outlier genes'). Single-tissue and multi-tissue outlier discovery. Single-tissue and multi-tissue outlier calling was restricted to autosomal lincRNA and protein-coding genes. For each tissue, an individual was called a single-tissue outlier for a particular gene if that individual had the largest absolute Z-score and the absolute value was at least 2. For each gene, the individual with the most extreme median Z-score taken across tissues was identified as a multi-tissue outlier for that gene provided the absolute median Z-score was at least 2. Therefore, each gene had at most one single-tissue outlier per tissue and one multi-tissue outlier. Under this definition an individual could be an outlier for multiple genes. In addition, we only tested for multi-tissue outliers among individuals with expression measurements for the gene in at least five tissues. To reduce cases where non-genetic factors may cause widespread extreme expression, we removed eight individuals that were multitissue outliers for 50 or more genes from all downstream analyses, including before single-tissue outlier discovery. Removing these individuals with extreme expression across many genes improved our rare variant enrichments, but the precise threshold mattered less (Extended Data Fig. 2g ). We chose the threshold of 50 to strike a balance between removing extreme individuals while not excluding a large proportion of our cohort. Replication of expression outliers. We calculated the proportion of single-tissue outliers discovered in one tissue that had | Z-score| ≥ 2 with the same direction of effect for the same gene in the replication tissue. Since certain groups of tissues were sampled in a specific subset of individuals, we evaluated the extent to which replication was influenced by the size and the overlap of the discovery and replication sets. We repeated the replication analysis with the discovery and replication in exactly 70 overlapping individuals for each pair of tissues with enough samples and compared the replication patterns to those obtained by using all individuals. To estimate the extent to which individual overlap biased replication estimates, for each pair of tissues with sufficient samples, we defined three disjoint groups of individuals: 70 individuals with data for both tissues, 69 distinct individuals with data in the first tissue, and 69 distinct individuals with data in the second tissue. We discovered outliers in the first tissue using the shared set of individuals then tested for replication using the same individuals in the second tissue. Then, for each gene, we added the identified outlier to the distinct set of individuals and tested the replication again in the second tissue. We repeated the process running the discovery in the second tissue and the replication in the first one. We compared the replication rates when using the same or different individuals for the discovery and replication.
We assessed the confidence of our multi-tissue outliers using cross-validation. We separated the tissue expression data randomly into two groups: a discovery set of 34 tissues and a replication set of 10 tissues. For t = 10, 15, 20, 25, and 30, we randomly sampled t tissues from the discovery set and performed outlier calling as described above. Owing to incomplete tissue sampling, the number of tissues supporting each outlier is at least five but less than t. We computed the replication rate as the proportion of outliers in the discovery set with | median Z-score| ≥ 1 or 2 in the replication set. We set no restriction on the number of tissues required for testing in the replication set. To calculate the expected replication rate, we randomly selected individuals in the discovery set with at least five tissues that expressed the gene and computed the replication rate. We repeated this process 10 times for each discovery set size. Quality control of genotypes and rare variant definition. We restricted our rare variant analyses to individuals of European descent, as they constituted the largest homogenous population within our dataset. We considered only autosomal variants that passed all filters in the VCF (those marked as PASS in the Filter column). Minor allele frequencies (MAFs) within the GTEx data were calculated from the 123 individuals of European ancestry with WGS data (average coverage 30× ). The MAF was the minimum of the reference and the alternate allele frequency where the allele frequencies of all alternate alleles were summed together. Rare variants were defined as having MAF ≤ 0.01 in GTEx, and for SNVs and indels we also required MAF ≤ 0.01 in the European population of the 1000 Genomes Project Phase 3 data 30 . To ensure that population structure among the individuals of European descent was unlikely to confound our results, we verified that the allele frequency distribution of rare variants included in our analysis (within 10 kb of a protein-coding or lincRNA gene, see below) was similar for the five European populations in the 1000 Genomes Project (Extended Data Fig. 4d ). Enrichment of rare and common variants near outlier genes. We assessed the enrichment of rare SNVs, indels and structural variants near outlier genes. Proximity was defined as within 10 kb of the transcription start site for most analyses. For Fig. 3 and Extended Data Figs 5, 7, 8, we included all variants within 10 kb of the gene, including the gene body, to also capture coding variants. In Fig. 3 and Extended Data Figs 5, 8 , we extended the window to 200 kb for enhancers and structural variants. For each gene with an outlier, we chose the remaining set of individuals tested for outliers at the same gene as non-outlier controls. We only considered genes that had both an outlier and at least one control. We stratified variants of each class into four minor allele frequency bins (0-1%, 1-5%, 5-10%, 10-25%) to compare the relative enrichments of rare and common variants. We also assessed the enrichment of SNVs at different Z-score cutoffs. Enrichment was defined as the ratio of the proportion of outliers with a variant whose frequency lies within the range to the corresponding proportion for non-outliers. This enrichment analysis is equivalent to the relative risk of having a nearby rare variant given outlier status. We used the asymptotic distribution of the log relative risk to obtain 95% Wald confidence intervals. Within our set of European individuals, we observed some individuals with minor admixture that had relatively more rare variants than the rest (Extended Data Fig. 1b ). We confirmed that inclusion of these admixed individuals did not substantially affect our results (Extended Data Fig. 1c ). We also calculated rare variant enrichments when restricting to variants outside protein-coding and lincRNA exons in the Gencode v.19 annotation (extending internal exons by 5 bp to capture canonical splice regions).
To measure the informativeness of variant annotations, we used logistic regression to model outlier status as a function of the feature of interest; this yielded log odds ratios with 95% Wald confidence intervals. Note that for the feature enrichment analysis in Fig. 3b and Extended Data Fig. 7 , we required that outliers and their gene-matched non-outlier controls have at least one rare variant near the gene. We standardized all features, including binary features, to facilitate comparison between features of different scale. We also calculated the proportion of overexpression outliers, underexpression outliers and non-outliers with a rare variant near the gene (within 10 kb for SNVs and indels and 200 kb for structural variants). To each outlier instance, we assigned at most one of the 12 rare variant classes that we considered ( Supplementary Table 3a ). If an outlier had rare variants from multiple classes near the relevant genes, we selected the class that was most significantly enriched among outliers. Annotation of variants. We obtained structural variant annotations from ref. 14 and computed features for rare SNVs and indels using three primary data sources: Roadmap Epigenomics 31 , CADD v.1.2 (ref. 19 ) and VEP v.80 (ref. 32 ). Promoter and enhancer annotation tracks were obtained from the Roadmap Epigenomics Project (http://www.broadinstitute.org/~ meuleman/reg2map/HoneyBadger2_ release/). We mapped 28 unique tissues in the GTEx project to 19 tissue groups in the Roadmap Project. Using these annotations, for each individual, we assessed whether each SNV or indel overlapped a promoter or enhancer region in at least one of the 19 Roadmap tissue groups. Features, including conservation [15] [16] [17] [18] , transcription factor binding and deleteriousness, were extracted from the full annotation tracks of the CADD v.1.2 release (downloaded 15 May 2015; http://cadd.gs.washington.edu/download). Finally, we obtained protein-coding and transcription-related annotations from VEP and LOFTEE. This information was provided in the GTEx v6p VCF file (described in ref. 12 ). Stop-gain and frameshift variants annotated as high-confidence loss-of-function variants by LOFTEE were assumed to trigger nonsense-mediated decay. We generated gene-level features described in Supplementary Table 3 . Allele-specific expression (ASE). We only considered sites with at least 30 total reads and at least five reads supporting each of the reference and alternate alleles. To minimize the effect of mapping bias, we filtered out sites that showed mapping bias in simulations 33 , that were in low mappability regions (ftp://hgdownload.cse. ucsc.edu/gbdb/hg19/bbi/wgEncodeCrgMapabilityAlign50mer.bw) or that were rare variants or within 1 kb of a rare variant in the given individual (the variants were extracted from the GTEx exome-sequencing data described in ref. 12 ). The first two filters were provided in the GTEx ASE data release. The third filter was applied to eliminate potential mapping artefacts that mimic genetic effects from rare variants. We measured ASE at each testable site as the absolute deviation of the reference-allele ratio from 0.5. For each gene, all testable sites in all tissues were included. We compared ASE in single-tissue and multi-tissue outliers at different Z-score thresholds to non-outliers using two-sided Wilcoxon rank-sum tests. To obtain a matched background, we only included a gene in the comparison when ASE data existed for both the outlier individual and at least one non-outlier. In the case of single-tissue outliers, we also required the tissue to match between the outlier and the non-outlier. All individuals that were neither multi-tissue outliers for the given gene nor single-tissue outliers for the gene in the corresponding tissue were included as non-outliers.
In cases where outliers had rare coding variants in the gene, if the rare variants were causing the extreme expression in cis, we expected to see ASE at the rare variant matching the direction of the effect. For underexpression outliers, we expected the (rare) minor allele to be underexpressed compared to the major allele. For overexpression outliers, we expected the minor allele to be overexpressed. To test this, we used the same filters as above, but looked exclusively at rare variants (instead of excluding them). We measured ASE as the minor-allele ratio: the number of reads supporting the minor allele over the total number of reads.
We also used ASE to evaluate the performance of both the genomic annotation model and RIVER (see below) by testing the association between allelic imbalance and model predictions using Fisher's exact test. Here, we defined allelic imbalance as the top 10% of the median absolute deviation, across tissues, of the referenceallele ratio from 0.5. Allele frequency measurements in UK10K. UK10K 3 VCF files of wholegenome cohorts were downloaded from https://www.ebi.ac.uk. We merged the Avon Longitudinal Study of Parents and Children (ALSPAC) EGAS00001000090 and the Department of Twin Research and Genetic Epidemiology (TWINSUK) EGAS00001000108 datasets for a total of 3,781 individuals. We counted the occurrence of all rare GTEx SNVs in Roadmap Epigenomics-annotated promoter regions among the UK10K samples. GTEx variants absent from the UK10K cohorts were assigned a count of 0. Definition of multi-tissue eGenes. We defined multi-tissue eGenes using two approaches. For the tissue-by-tissue approach, we obtained lists of significant eGenes (q value ≤ 0.05) for each of the 44 tissues from the GTEx v6p release. The second approach used cis-eQTLs with shared effects across tissues estimated by the RE2 model of the Meta-Tissue software 34 , as described in ref. 12. We chose, for each gene, the variant with the lowest nominal P value from the RE2 model. We then determined the number of tissues in which this variant-gene pair showed a cis-eQTL effect (m value ≥ 0.9 (ref. 34) ). For each of the 18,380 genes tested for multi-tissue outliers, we calculated the number of tissues in which the gene appeared as a significant eGene (tissue-by-tissue approach) or had a shared eQTL effect (Meta-Tissue approach). To show that the enrichment of outlier genes as multi-tissue eGenes was not confounded by gene expression level, using the Meta-Tissue results, we stratified genes tested for multi-tissue outliers into RPKM deciles and repeated the comparison between genes with and without a multitissue outlier. When comparing the enrichment for eGenes among constrained and disease gene lists, we classified the top n Meta-Tissue eGenes (ranked by nominal P value from the RE2 model) as multi-tissue eGenes and considered the remaining genes as background. We selected n to match the number of multi-tissue outliers in the comparison. Evolutionary constraint of genes with multi-tissue outliers. We obtained gene-level estimates of evolutionary constraint from the Exome Aggregation Consortium 35 (http://exac.broadinstitute.org/, ExAC release v.0.3). We intersected the 17,351 autosomal lincRNA and protein-coding genes with constraint data from ExAC with the 18,380 genes tested for multi-tissue outliers from GTEx, yielding 14,379 genes for further analysis (3,897 and 10,482 genes with and without a multi-tissue outlier, respectively). We examined three functional constraint scores from the ExAC database: synonymous Z-score, missense Z-score and probability of loss-of-function intolerance (pLI). Synonymous-and missense-intolerant genes were defined as those with corresponding Z-scores above the 90th percentile. We defined loss-of-function intolerant genes as those with a pLI score above 0.9, following the guidelines provided by ExAC. We calculated odds ratios and 95% confidence intervals for the enrichment of genes with multi-tissue outliers in these lists using a Fisher's exact test. We repeated this analysis for three other gene sets: 19,182 multi-tissue eGenes from GTEx v6p defined using Meta-Tissue, 9, 480 reported GWAS genes from the NHGRI-EBI catalogue 36 (http://www.ebi.ac.uk/ gwas, accessed 30 November 2015) and 3,576 OMIM genes (http://omim.org/, accessed 26 May 2016).
We tested for a difference in the mean constraint for genes with multi-tissue outliers and genes with multi-tissue eQTLs using ANOVA. For each constraint score in ExAC, we treated the score for each gene as the response and the status of the gene as having a multi-tissue outlier and/or a multi-tissue eQTL as a categorical predictor with four classes. After fitting the model, we performed a Tukey's range test to determine whether there was a significant difference in the mean constraint between genes with a multi-tissue outlier but no multi-tissue eQTL and genes with a multi-tissue eQTL but no multi-tissue outlier. Overlap of genes with multi-tissue outliers and disease genes. We examined the enrichment of genes with multi-tissue outliers in eight disease gene lists: the GWAS catalogue and OMIM (described above), as well as ClinVar (6,279 genes; http://www.ncbi.nlm.nih.gov/clinvar/), OrphaNet (3,451 genes; http://www.orpha. net/), ACMG 20 (58 genes; http://www.ncbi.nlm.nih.gov/clinvar/docs/acmg/), Developmental Disorders Genotype-to-Phenotype 37 (DDG2P; 1,693 genes; http://www.ebi.ac.uk/gene2phenotype/), and two curated gene lists of 86 cardiovascular disease genes and 55 cancer genes (described below). We computed odds ratios and 95% confidence intervals using a Fisher's exact test to compare each disease gene list to the genes with multi-tissue outliers and repeated the comparison for genes with multi-tissue eQTLs.
Heritable cancer predisposition and heritable cardiovascular disease gene lists were curated by local experts in clinical and laboratory-based genetics in the two respective areas (Stanford Medicine Clinical Genomics Service, Stanford Cancer Center's Cancer Genetics Clinic and Stanford Center for Inherited Cardiovascular Disease). Genes were included if both the clinical and laboratory-based teams agreed there was sufficient published evidence to support using variants in these genes in clinical decision making.
For each of the eight disease gene lists above and for genes with multi-tissue outliers or multi-tissue eQTLs, we computed the number of variants (SNVs and indels within 10 kb and structural variants within 200 kb of the gene, including the gene body) at each gene in the 123 individuals of European ancestry with WGS
data. For each gene list and for each MAF bin (0-1%, 1-5%, 5-10%, 10-25%), we compared the mean number of variants near genes in the list to the mean number near all other annotated autosomal protein-coding and lincRNA genes using a two-sided t-test. The RIVER integrative model for predicting regulatory effects of rare variants. RIVER (RNA-informed variant effect on regulation) is a hierarchical Bayesian model that predicts the regulatory effects of rare variants by integrating gene expression with genomic annotations. The RIVER model consists of three layers: a set of nodes G = G 1 ,..., G P in the topmost layer representing P observed genomic annotations over all rare variants near a particular gene; a latent binary variable F in the middle layer representing the unobserved functional regulatory status of the rare variants; and one binary node E in the final layer representing expression outlier status of the nearby gene. We model each conditional probability distribution as follows:
with parameters β and θ and hyper-parameters λ and C.
Because F is unobserved, the RIVER log-likelihood objective over instances
n N F n n n 1 0 1 n is non-convex. We therefore optimize model parameters using Expectation-Maximization 38 (EM) as follows:
In the E-step, we compute the posterior probabilities (w n (i) ) of the latent variables F n given current parameters and observed data. For example, at the ith iteration, the posterior probability of F n = 1 for the nth instance is
n n i n n i F n n i n n i
In the M-step, at the ith iteration, given the current estimates ω (i) , the parameters (β (i + 1)* ) are estimated as
where λ is an L2 penalty hyper-parameter derived from the Gaussian prior on β.
The parameter θ gets updated as:
where I is an indicator operator, t is the binary value of expression E n , s is the possible binary values of F n , and C is a pseudo count derived from the Beta prior on θ. The E and M steps are applied iteratively until convergence. RIVER application to the GTEx cohort. As input, RIVER requires a set of genomic features G and a set of corresponding expression outlier observations E, each over instances of individual and gene pairs. Using the variant annotations described above, we generated site-level genomic features for the 116 European individuals with GTEx WGS data that had fewer than 50 multi-tissue outliers. We then collapsed these features for all rare SNVs within 10 kb of each transcription start site to generate the gene-level features that are described in Supplementary Table 3b . This produced a matrix of genomic features G of size (116 individuals × 1,736 genes) × (112 genomic features), where we standardized features before use. For the values of E, we defined any individual with | median Z-score| ≥ 1.5 as an outlier if expression was observed in at least five tissues; the remaining individuals were labelled as non-outliers for the gene. We used this more lenient threshold in order to obtain a sufficiently large set of outliers for robust training and testing. In total, we extracted 48,575 instances where an individual had at least one rare variant within 10 kb of the transcription start site of a gene.
To train and evaluate RIVER on the GTEx cohort, we used the 3,766 instances of individual and gene pairs where two individuals had the same rare SNVs near a particular gene. We held out those instances and trained RIVER parameters with the remaining instances. RIVER requires two hyper-parameters λ and C. To select λ, we first applied an L2-regularized multivariate logistic regression with features G and response variable E, selecting λ with the minimum squared error via tenfold cross-validation (we selected λ = 0.01). We selected C = 50, informed simply by the total number of training instances available, as validation data were not available for extensive cross-validation. Initial parameters for EM were set to θ = (P(E = 0 | F = 0), P(E = 1 | F = 0), P(E = 0 | F = 1), P(E = 1 | F = 1)) = (0.99, 0.01, 0.3, 0.7) and β from the multivariate logistic regression above, although different initializations did not significantly change the final parameters (Extended Data Fig. 9b ).
The 3,766 held-out pairs of instances were used to create a labelled evaluation set. For one of the two individuals from each pair, we estimated the posterior probability of a functional rare variant P (F | G, E, β, θ) . The outlier status of the second individual, whose data were not observed either during training or prediction, was then treated as a 'label' of the true status of functional effect F. Using this labelled set, we compared the RIVER score to the posterior P (F | G, β) estimated from the plain L2-regularized multivariate logistic regression model with genomic annotations alone. We produced receiver operating characteristic curves and computed areas under the curve (AUCs) for both models, testing for significant differences using DeLong's method 29 . This analysis relied on outlier status reflecting the consequences of rare variants. Indeed, pairs of individuals who shared rare variants tended to have highly similar outlier status even after regressing out effects of common variants (Kendall's τ rank correlation, P < 2.2 × 10 −16 ). We repeated this evaluation, varying the median Z-score threshold used to define outliers, and we also compared RIVER to individual features that were strongly enriched among outliers as well as PolyPhen 39 and SIFT 40 . Supervised model integrating expression and genomic annotation. To assess the information gained by incorporating gene expression data in the prediction of functional rare variants, we applied a simplified supervised approach to a limited dataset. We used the instances where two individuals had the same rare SNVs to create a labelled training set where the outlier status of the second individual was used as the response variable. We then trained a logistic regression model with only two features: (1) the outlier status of the first individual and (2) a single genomic feature value, such as CADD or deleterious annotation of genetic variants using neural networks (DANN). We estimated parameters from the entire set of rare-variant-matched pairs using logistic regression to determine the log odds ratio and corresponding P value of expression status as a predictor. While this approach was not amenable to training a full predictive model over all genomic annotations jointly given the limited number of instances, it provided a consistent estimate of the log odds ratio of outlier status. We tested five genomic predictors: CADD 19 , DANN 41 , transcription-factor-binding site annotations, PhyloP scores 15 and one aggregated feature: the posterior probability from a multivariate logistic regression model learned with all genomic annotations. RIVER assessment of pathogenic ClinVar variants. We downloaded variants from the ClinVar database 21 (accessed 04 May 2015) and searched for these disease variants within the set of rare variants segregating in the GTEx cohort. Any disease variant reported as pathogenic, likely pathogenic or a risk factor for disease was considered pathogenic. We further categorized the pathogenic variants as likely regulatory if they were annotated as splice-site variants, synonymous or nonsense, whereas missense variants were considered unlikely to have a regulatory effect. To explore RIVER scores for those pathogenic variants, all instances were used for training RIVER. We then computed a posterior probability P (F | G, E, β, θ) for each instance coinciding with a pathogenic ClinVar variant.
Stability of estimated parameters with different parameter initializations.
We tried several different initialization parameters for β and θ to explore how this affected the estimated parameters. We initialized a noisy β by adding K% Gaussian noise compared to the mean of β with fixed θ (for K = 10, 20, 50 100, 200, 400, 800). For θ, we fixed P(E = 1 | F = 0) and P(E = 0 | F = 0) as 0.01 and 0.99, respectively, and initialized (P(E = 1 | F = 1), P(E = 0 | F = 1)) as (0.1, 0.9), (0.4, 0.6) and (0.45, 0.55) instead of (0.3, 0.7) with β fixed. For each parameter initialization, we computed Spearman rank correlations between parameters from RIVER using the original initialization and the alternative initializations. We also investigated how many instances within top 10% of posterior probabilities from RIVER under the original settings were replicated in the top 10% of posterior probabilities under the alternative initializations (replication accuracy in Extended Data Fig. 9b ). Validation of large-effect rare variants using CRISPR-Cas9 genome editing. To select rare, coding SNVs for validation by CRISPR-Cas9 editing, we first restricted to the (gene, individual, variant) tuples identified in multi-tissue outliers without a rare structural variant or a rare indel within 200 kb or 10 kb of the gene, respectively. all tissues, and both axes were hierarchically clustered. White denotes missing values, and tissues are coloured as in Fig. 1 . PEER factors captured slightly different covariates across tissues, with a noticeable difference between the brain and other tissues. c, Rare variant enrichments as in Fig. 2a for different levels of PEER correction. The fully corrected data show substantially stronger rare variant enrichments than the two partially corrected datasets. . When restricting to 70 individuals, the replication rates decreased more for discovery tissues with larger sample sizes in the full dataset, indicating that replication rates were underestimated for tissues with small sample sizes. b, Correlation between replication in the 70 individuals used for discovery and replication assessed in a set of 70 individuals that included the outlier individual and 69 individuals excluded from the discovery set (Pearson's correlation, P < 2.2 × 10 −16 ). Replication was higher when computed in the discovery individuals rather than in a distinct set of individuals. c, Single-tissue outlier replication using all individuals, as in Fig. 1b , but data are only shown for pairs with at least 70 overlapping individuals. Tissue pairs with insufficient overlap are in grey. d, For each pair of tissues with sufficient samples, outlier discovery and replication using 70 individuals sampled in both tissues. The replication values decreased compared with replication performed in all individuals (c), particularly for tissues with large sample sizes in the complete dataset. However, the pattern of replication, with more similar tissues having higher replication rates, is maintained. e, For each tissue, the proportion of (individual, gene) outlier pairs where the individual was also a multi-tissue outlier for the gene. This proportion was positively correlated with the tissue sample size (P = 1.4 × 10 −10 ). Points are coloured by tissue as in Fig. 1 . The individuals with an excess of rare variants probably had African or Asian admixture. c, Enrichments as in Fig. 2a and excluding individuals with > 60,000 rare variants (circled in b), which did not substantially affect the enrichment patterns. d, European population allele frequency distributions in the 1000 Genomes Project of rare SNVs and indels used in our analysis. The rare variants included in our analysis were constrained to have MAF ≤ 0.01 in the 1000 Genomes European super population, but they were also relatively rare in each of the individual European populations.
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Extended Data Figure 5 | Comparison of overexpression and underexpression outliers. a, ASE at rare exonic variants. ASE is shown as the ratio of the number of reads supporting the minor allele to the total number of reads at the site. If the rare variant is driving the extreme expression, we expect this ratio to be below 0.5 for underexpression outliers and above 0.5 for overexpression outliers. Rare coding variants were enriched for ASE in the direction of the extreme expression effect (two-sided Wilcoxon rank-sum tests, each nominal P < 4.0 × 10 −8 ). b, Expression level distribution of all genes and genes with overexpression or underexpression outliers. Expression is shown as the log 2 of the median (RPKM + 2), where the median was first taken across individuals in each tissue then across expressed tissues for each gene. For genes with low expression, even an RPKM of 0 may not yield a Z-score ≤ −2. Indeed, underexpression outliers were depleted among low expressed genes whereas the opposite was true of overexpression outliers (two-sided Wilcoxon rank-sum test comparing to all genes, P < 2.2 × 10 −16 for both overexpression and underexpression). c, Feature enrichments (as in Fig. 3b) shown separately for over and underexpression outliers.
Extended Data Figure 7 | Enrichment of an extended list of functional genomic annotations. log odds ratios and 95% Wald confidence intervals from logistic regression models of outlier status as a function of each genomic feature. Features were calculated among rare SNVs within 10 kb of the gene. When more than one feature corresponded to the same genomic annotation (for example, the number or the presence of rare variants in a splice region; Supplementary Table 3b ), the feature with the highest enrichment is shown. Lighter shading indicates a non-significant log odds ratio (nominal P > 0.05). 
nature research | life sciences reporting summary
Initial submission Revised version Final submission
Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity. 
Data exclusions
Describe any data exclusions. We used the GTEX samples included in the eQTL analyses. The data inclusion/ exclusion criteria are described in that manuscript (submitted concurrently). We further excluded any individuals with more than 50 multi-tissue outliers, as described in the methods.
Replication
Describe whether the experimental findings were reliably reproduced.
We validated the effects on expression of four rare variants via CRISPR/Cas9 genome editing. We attempted to validate two additional variants but excluded them from our analysis because they failed to amplify successfully, so we could not accurately measure their effect.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Order of sample processing for library preparation and sequencing was randomized to avoid batch effects.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding took place.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance. Describe the software used to analyze the data in this study.
RIVER is available at https://bioconductor.org/packages/release/bioc/html/ RIVER.html. Additionally, the code for running analyses and producing the figures throughout the manuscript is available separately (https://github.com/joed3/ GTExV6PRareVariation).
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Residual biospecimens are available to all researchers according to the Genotype-Tissue Expression (GTEx) project biospecimens access policy. The policy and related forms can be found on the GTEx Portal (gtexportal.org) under the Biobank Tab.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). The human research participants and relevant covariates are described in this manuscript and the GTEx eQTL manuscript submitted concurrently.
